Reference : Impact of estetrol on breast cancer development, metastatic dissemination and angiogenesis
Scientific congresses and symposiums : Poster
Human health sciences : Oncology
http://hdl.handle.net/2268/197928
Impact of estetrol on breast cancer development, metastatic dissemination and angiogenesis
English
[fr] Impact de l'estétrol sur la progression tumorale mammaire, la dissémination métastatique et l'angiogenèse
Gallez, Anne mailto [Université de Liège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques >]
Gérard, Céline mailto [Université de Liège > > R&D Direction : Chercheurs ULiège en mobilité >]
Blacher, Silvia mailto [Centre Hospitalier Universitaire de Liège - CHU > > Centre d'oncologie >]
Noël, Agnès mailto [Université de Liège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement >]
Foidart, Jean-Michel mailto [Université de Liège > Département des sciences cliniques > Département des sciences cliniques >]
Pequeux, Christel mailto [Université de Liège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques >]
2016
1
No
No
National
Giga Cancer Day
25 janvier 2016 au 25 janvier 2016
Giga-Cancer , Université de Liège
Liège
Belgique
[en] Estetrol ; Hormone Replacement Therapy ; Breast Cancer
[en] The increased risk of breast cancer and thromboembolism in women who take Hormone Replacement Therapy (HRT) currently is a major public health problem. The discovery of novel molecules with better safety profile would provide useful advances for patient care. Estretrol (E4) appears as a promising candidate for HRT. Indeed, in contrast to current treatment containing ethinyl estradiol or estradiol (E2), E4 has a minimal impact on liver cells activity supporting a decreased incidence on thromboembolic events. In preclinical studies, E4 has been effective against the main symptoms of menopause such as hot flushes, vaginal atrophy, and osteoporosis, from a starting dose of 0.3 mg/kg/day. The aim of this study was to define the impact of E4 on breast cancer development when it is used at concentrations effective for menopause symptom relief.
Treatment of estrogen receptor (ER)-positive breast cancer-developing mice (MMTV-PyMT) with several concentrations of E4 has shown that 0.3 mg/kg/day E4 did not increase tumor development and metastasis dissemination. However, at 3mg/kg/day, E4 increased the growth of hormone-dependent tumors and their metastatic dissemination in ovariectomized and intact mice. This effect was similar to the one observed with E2 used at 0.08 mg/kg/day. In an in vivo model of ER-negative tumors, we observed that 3mg/kg/day E4 improved tumor growth by increasing angiogenesis, and subsequently decreasing necrosis and tumor hypoxia. In contrast, 0.3 mg/kg/day E4 did not induce any of these effects on ER-negative tumors and tumor microenvironment.
In conclusion, we have shown that 0.3 mg/kg/day E4, already reported to prevent menopause symptoms, does not increase breast tumor growth, metastasis dissemination, and angiogenesis. However, similarly to E2, higher concentrations of E4 are pro-tumorous. These results support that E4, if it is used in strictly controlled clinical applications, could have no or only limited impact on breast cancer.
Laboratoire de Biologie des Tumeurs et du Développement (LBTD) - Giga Cancer
Fonds Léon Fredericq
Etude des mécanismes d'activation des récepteurs aux oestrogènes par l'estétrol et/ou la progestérone dans le sein normal et tumoral
Researchers
http://hdl.handle.net/2268/197928
CONFIDENTIEL

There is no file associated with this reference.

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.